Publications | PubMed=8221668 Jelinek D.F., Ahmann G.J., Greipp P.R., Jalal S.M., Westendorf J.J., Katzmann J.A., Kyle R.A., Lust J.A. Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. Cancer Res. 53:5320-5327(1993) PubMed=8943038; DOI=10.1073/pnas.93.24.13931 Bergsagel P.L., Chesi M., Nardini E., Brents L.A., Kirby S.L., Kuehl W.M. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc. Natl. Acad. Sci. U.S.A. 93:13931-13936(1996) PubMed=10583232; DOI=10.1046/j.1365-2141.1999.01705.x Puthier D., Derenne S., Barille S., Moreau P., Harousseau J.-L., Bataille R., Amiot M. Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br. J. Haematol. 107:392-395(1999) DOI=10.1007/0-306-46877-8_4 Jernberg-Wiklund H., Nilsson K. Multiple myeloma cell lines. (In) Human cell culture. Vol. 3. Cancer Cell Lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York (2000) PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2 Drexler H.G., Matsuo Y. Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia. Leuk. Res. 24:681-703(2000) DOI=10.1016/B978-0-12-221970-2.50457-5 Drexler H.G. The leukemia-lymphoma cell line factsbook. (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001) PubMed=11154231; DOI=10.1182/blood.V97.2.516 Hjertner O., Hjorth-Hansen H., Borset M., Seidel C., Waage A., Sundan A. Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Blood 97:516-522(2001) PubMed=11157491; DOI=10.1182/blood.V97.3.729 Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A., Kuehl W.M., Bergsagel P.L. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 97:729-736(2001) PubMed=16956823 Bataille R., Jego G., Robillard N., Barille-Nion S., Harousseau J.-L., Moreau P., Amiot M., Pellat-Deceunynck C. The phenotype of normal, reactive and malignant plasma cells Identification of 'many and multiple myelomas' and of new targets for myeloma therapy. Haematologica 91:1234-1240(2006) PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003 Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J., Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T., Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C., Brents L.A., Kumar S.K., Greipp P., Dispenzieri A., Bryant B., Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M., Stewart A.K., Carpten J.D., Bergsagel P.L. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12:131-144(2007) PubMed=18647998; DOI=10.1093/jncimonographs/lgn011 Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M. Characterization of MYC translocations in multiple myeloma cell lines. J. Natl. Cancer Inst. Monogr. 39:25-31(2008) PubMed=19344406; DOI=10.1111/j.1365-2141.2009.07647.x Voorhees P.M., Chen Q., Small G.W., Kuhn D.J., Hunsucker S.A., Nemeth J.A., Orlowski R.Z. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br. J. Haematol. 145:481-490(2009) PubMed=21173094; DOI=10.3324/haematol.2010.033456 Moreaux J., Klein B., Bataille R., Descamps G., Maiga S., Hose D., Goldschmidt H., Jauch A., Reme T., Jourdan M., Amiot M., Pellat-Deceunynck C. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 96:574-582(2011) PubMed=23992230; DOI=10.1111/ejh.12192 Greenberg A.J., Walters D.K., Kumar S.K., Rajkumar S.V., Jelinek D.F. Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels. Eur. J. Haematol. 91:504-513(2013) PubMed=24013424; DOI=10.4161/cc.26193 Walters D.K., Arendt B.K., Jelinek D.F. CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells. Cell Cycle 12:3175-3183(2013) PubMed=25015330; DOI=10.18632/oncotarget.2159 Arendt B.K., Walters D.K., Wu X., Tschumper R.C., Jelinek D.F. Multiple myeloma cell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation. Oncotarget 5:5686-5699(2014) PubMed=25688540; DOI=10.1002/cyto.a.22643 Maiga S., Brosseau C., Descamps G., Dousset C., Gomez-Bougie P., Chiron D., Menoret E., Kervoelen C., Vie H., Cesbron A., Moreau-Aubry A., Amiot M., Pellat-Deceunynck C. A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines. Cytometry A 87:285-288(2015) CLPUB00604 Chow S. Targeted capture and sequencing of immunoglobulin rearrangements in multiple myeloma to enable detection of minimal residual disease. Thesis MSc (2017), University of Toronto, Canada PubMed=32123307; DOI=10.1038/s41375-020-0785-1 Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B., Sirota M., Wiita A.P. Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis. Leukemia 34:2754-2765(2020) |